Security key
403783103
GYRE THERAPEUTICS, INC. - Common Stock, par value $0.001 per share (GYRE)
CUSIP: 403783103
Q4 2023 13F Holders as of 31 Dec 2023
- Security type / class
- Equity / Common Stock, par value $0.001 per share
- Total 13F shares
- 606,775
- Total 13F value
- $15,589,189
- Share change
- +606,509
- SEC-reported price per share
- $25.69
- Number of holders
- 15
- Value change
- +$15,582,189
- Number of buys
- 14
- Shares outstanding
- 124,924,768
Holder snapshot
5 signals
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q4 2023
Institutions
15
Top holders
10
GYRE full security history
Ownership snapshot
Full 13F holder table
Newer quarter: Q1 2024
GYRE THERAPEUTICS, INC. SEC filings
GYRE THERAPEUTICS, INC. company facts
Broader feeds
Reporting periods
Holder history for CUSIP 403783103
Recent filing periods:
Ownership snapshot
Top reported holders of GYRE - GYRE THERAPEUTICS, INC. - Common Stock, par value $0.001 per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Eddie Williams
Disclosed value leader
Eddie Williams
Comparable rows
0/8
Latest evidence
20 Nov 2023
3/4/5
Highest disclosed value: $16,358
8 rows are not safely comparable across share classes.
Showing 1-6 of 8 holder rows.
Quick read
Eddie Williams has the largest disclosed position value at $16.4K.
0 of 8 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens Eddie Williams's linked filing trail.
Disclosed position value
Top 5
Eddie Williams
$16.4K
Geoffrey Ling MD
$14.9K
Errol B. Desouza
$14K
Howard Levy
$11.3K
Grant E. Blouse
$4.4K
Value bars compare disclosed positions; verify each figure against the linked filing evidence.
Detailed SEC evidence table Showing 1-6 of 8 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Eddie Williams |
3/4/5
Director
|
—
class O/S missing
|
$16,358
34,804 shares
|
— | 07 Jan 2022 |
| Geoffrey Ling MD |
3/4/5
Director
|
—
class O/S missing
|
$14,941
31,790 shares
|
— | 07 Jan 2022 |
| Errol B. Desouza |
3/4/5
Director
|
—
class O/S missing
|
$14,006
29,801 shares
|
— | 01 Oct 2021 |
| Howard Levy |
3/4/5
Chief Medical Officer
|
—
class O/S missing
|
$11,293
24,029 shares
|
— | 09 Aug 2021 |
| Grant E. Blouse |
3/4/5
Chief Scientific Officer
|
—
class O/S missing
|
$4,426
9,417 shares
|
— | 09 Aug 2022 |
| Charles C. Wu |
3/4/5
Chief Executive Officer, Director
|
—
class O/S missing
|
—
170,417 shares
|
— | 20 Nov 2023 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q4 2023
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
15
Shares
606,775
Rows available
15
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q4 2023 vs Q1 2026 Across Filers
Q1 2026 holders
55
Q4 2023 holders
15
Holder diff
-40
| Investor | Q1 2026 Shares | Q4 2023 Shares | Share Diff | Share Chg % | Q1 2026 value | Q4 2023 value | Value change | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend